# US 2023/0265203 A1 · Use of anti-cd40 antibodies for treatment of lupus nephritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265203 A1
- Document ID: US20230265203A1
- Status: Published application
- Kind: A1
- Application number: 17/962,099
- Filed: 2022-10-07
- Published: 2023-08-24
- Earliest claimed: 2015-09-01
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Scott Ronald BRODEUR; Thomas B. FREEMAN; Gerald Henry Nabozny; Meera RAMANUJAM; Paul SCHOLL; Juergen STEFFGEN
- Web page: https://patentgrep.com/patent/US20230265203A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 13/12: of the kidneys
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.

## Claims

### Claim 1

A method of treating or preventing lupus nephritis, the method comprising administering to a human patient in need thereof a therapeutically effective amount of a humanized antibody that specifically binds human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
a) a heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO: 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17; and
b) the light chain CDR1 sequence has a sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:22 through SEQ ID NO:23, and a light chain CDR3 sequence selected from the group consisting of SEQ ID NO:24 through SEQ ID NO:25.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 10, a heavy chain CDR2 sequence of SEQ ID NO:13 and a heavy chain CDR3 sequence of SEQ ID NO:16; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:19, a light chain CDR2 sequence of SEQ ID NO:22 and a light chain CDR3 sequence of SEQ ID NO:24.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 9, a heavy chain CDR2 sequence of SEQ ID NO:14 and a heavy chain CDR3 sequence of SEQ ID NO:16; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:20, a light chain CDR2 sequence of SEQ ID NO:22 and a light chain CDR3 sequence of SEQ ID NO:24.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 11, a heavy chain CDR2 sequence of SEQ ID NO:15 and a heavy chain CDR3 sequence of SEQ ID NO:17; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:23 and a light chain CDR3 sequence of SEQ ID NO:25.

### Claim 5

A method of treating or preventing lupus nephritis, the method comprising administering to a human patient in need thereof a therapeutically effective amount of a humanized monoclonal antibody or antibody fragment that specifically binds human CD40, said antibody or antibody fragment having a heavy chain variable domain and a light chain variable region comprising the amino acid sequences selected from:
SEQ ID NO:27 and SEQ ID NO:26, respectively;
SEQ ID NO:28 and SEQ ID NO:26, respectively;
SEQ ID NO:29 and SEQ ID NO:26, respectively;
SEQ ID NO:30 and SEQ ID NO:26, respectively;
SEQ ID NO:32 and SEQ ID NO:31, respectively;
SEQ ID NO:33 and SEQ ID NO:31, respectively;
SEQ ID NO:34 and SEQ ID NO:31, respectively;
SEQ ID NO:35 and SEQ ID NO:31, respectively;
SEQ ID NO:37 and SEQ ID NO:36, respectively;
SEQ ID NO:38 and SEQ ID NO:36, respectively;
SEQ ID NO:39 and SEQ ID NO:36, respectively;
SEQ ID NO:40 and SEQ ID NO: 36, respectively;
SEQ ID NO: 44 and SEQ ID NO: 43, respectively;
SEQ ID NO: 53 and SEQ ID NO: 52, respectively; and
SEQ ID NO: 58 and SEQ ID NO: 56, respectively.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The method of claim 5, wherein the humanized monoclonal antibody or antibody fragment comprises:
a heavy chain comprising SEQ ID NO:30 and a light chain comprising SEQ ID NO:26;
a heavy chain comprising SEQ ID NO:35 and a light chain comprising SEQ ID NO:31; or
a heavy chain comprising SEQ ID NO:40 and a light chain comprising SEQ ID NO:36.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration.

### Claim 9

A pharmaceutical composition comprising
(a) a humanized antibody that specifically binds human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
i) the heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO: 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17; and
ii) the light chain CDR1 sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:22 through SEQ ID NO:23, and a light chain CDR3 sequence selected from the group consisting of SEQ ID NO:24 through SEQ ID NO:25; and
(b) a buffer, a stabilizing agent, and, optionally, a pH adjusting agent.

### Claim 10 (depends on 5)

The method of claim 5, wherein the humanized monoclonal antibody or antibody fragment comprises:
a heavy chain comprising SEQ ID NO:44 and a light chain comprising SEQ ID NO:43;
a heavy chain comprising SEQ ID NO:53 and a light chain comprising SEQ ID NO:52; or
a heavy chain comprising SEQ ID NO:58 and a light chain comprising SEQ ID NO:56.
